Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q6PCB0
UPID:
VWA1_HUMAN
Alternative names:
-
Alternative UPACC:
Q6PCB0; A8K692; B3KUA1; E9PB53; Q7L5D7; Q9H6J5
Background:
Von Willebrand factor A domain-containing protein 1 plays a pivotal role in skeletal muscle organization and neuromuscular junction formation. Its involvement in matrix assembly underscores its importance in cellular structure and function.
Therapeutic significance:
Linked to Neuropathy, hereditary motor, with myopathic features, this protein's understanding could pave the way for innovative treatments targeting muscle weakness and mobility challenges.